BR112020023623A2 - derivados de benzodiazepina e seus usos - Google Patents

Info

Publication number

BR112020023623A2

BR112020023623A2 BR112020023623-3A BR112020023623A BR112020023623A2 BR 112020023623 A2 BR112020023623 A2 BR 112020023623A2 BR 112020023623 A BR112020023623 A BR 112020023623A BR 112020023623 A2 BR112020023623 A2 BR 112020023623A2

Authority

BR

Brazil

Prior art keywords

alkyl

compound

mmol

fact

independently

Prior art date

2018-05-29

Links

• Espacenet
• Global Dossier
• Discuss

• 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title description 2
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 491
• 238000000034 method Methods 0.000 claims abstract description 64
• 210000004027 cell Anatomy 0.000 claims description 135
• -1 isothiocyanide Chemical compound 0.000 claims description 116
• 125000000217 alkyl group Chemical group 0.000 claims description 99
• 125000003118 aryl group Chemical group 0.000 claims description 69
• 238000006243 chemical reaction Methods 0.000 claims description 66
• 125000001072 heteroaryl group Chemical group 0.000 claims description 62
• 206010028980 Neoplasm Diseases 0.000 claims description 59
• 125000005647 linker group Chemical group 0.000 claims description 45
• 150000003839 salts Chemical class 0.000 claims description 44
• 239000000427 antigen Substances 0.000 claims description 39
• 108091007433 antigens Proteins 0.000 claims description 39
• 102000036639 antigens Human genes 0.000 claims description 39
• 229910052739 hydrogen Inorganic materials 0.000 claims description 39
• 239000001257 hydrogen Substances 0.000 claims description 39
• 239000003795 chemical substances by application Substances 0.000 claims description 38
• 230000008685 targeting Effects 0.000 claims description 38
• 201000011510 cancer Diseases 0.000 claims description 34
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 34
• 229910052736 halogen Inorganic materials 0.000 claims description 33
• 150000002367 halogens Chemical class 0.000 claims description 32
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
• 125000005842 heteroatom Chemical group 0.000 claims description 25
• 239000008194 pharmaceutical composition Substances 0.000 claims description 25
• 102000005962 receptors Human genes 0.000 claims description 23
• 108020003175 receptors Proteins 0.000 claims description 23
• 239000013543 active substance Substances 0.000 claims description 22
• 125000000524 functional group Chemical group 0.000 claims description 22
• 125000000623 heterocyclic group Chemical group 0.000 claims description 22
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 21
• 239000000126 substance Substances 0.000 claims description 21
• 125000001424 substituent group Chemical group 0.000 claims description 21
• 125000003545 alkoxy group Chemical group 0.000 claims description 20
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 18
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 18
• 125000004429 atom Chemical group 0.000 claims description 17
• 125000003342 alkenyl group Chemical group 0.000 claims description 15
• 229910052757 nitrogen Inorganic materials 0.000 claims description 15
• 230000000269 nucleophilic effect Effects 0.000 claims description 15
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
• 239000011230 binding agent Substances 0.000 claims description 14
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
• 210000004881 tumor cell Anatomy 0.000 claims description 14
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
• 229940127089 cytotoxic agent Drugs 0.000 claims description 13
• 229910052760 oxygen Inorganic materials 0.000 claims description 13
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 12
• 239000003937 drug carrier Substances 0.000 claims description 12
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 12
• 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims description 12
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
• 229920001184 polypeptide Polymers 0.000 claims description 12
• 241000124008 Mammalia Species 0.000 claims description 11
• 229920002472 Starch Polymers 0.000 claims description 11
• 239000002246 antineoplastic agent Substances 0.000 claims description 11
• 235000019698 starch Nutrition 0.000 claims description 11
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 10
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 10
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 10
• 125000002947 alkylene group Chemical group 0.000 claims description 10
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 10
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 9
• 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 9
• 239000008107 starch Substances 0.000 claims description 9
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
• 150000001412 amines Chemical class 0.000 claims description 8
• 238000003776 cleavage reaction Methods 0.000 claims description 8
• 125000001188 haloalkyl group Chemical group 0.000 claims description 8
• 150000002576 ketones Chemical class 0.000 claims description 8
• 230000007017 scission Effects 0.000 claims description 8
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 7
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 7
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 7
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 7
• 229910006069 SO3H Inorganic materials 0.000 claims description 7
• HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 7
• 150000001336 alkenes Chemical class 0.000 claims description 7
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 7
• 150000001540 azides Chemical class 0.000 claims description 7
• 150000001993 dienes Chemical class 0.000 claims description 7
• 150000004820 halides Chemical class 0.000 claims description 7
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
• 229920006395 saturated elastomer Polymers 0.000 claims description 7
• 235000000346 sugar Nutrition 0.000 claims description 7
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 7
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 6
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 6
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 6
• 125000003282 alkyl amino group Chemical group 0.000 claims description 6
• 125000000539 amino acid group Chemical group 0.000 claims description 6
• 229910052799 carbon Inorganic materials 0.000 claims description 6
• 125000004432 carbon atom Chemical group C* 0.000 claims description 6
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
• 229910052717 sulfur Inorganic materials 0.000 claims description 6
• 108010038807 Oligopeptides Proteins 0.000 claims description 5
• 102000015636 Oligopeptides Human genes 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
• 125000001302 tertiary amino group Chemical group 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 102000001301 EGF receptor Human genes 0.000 claims description 4
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 4
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 4
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 4
• 125000004434 sulfur atom Chemical group 0.000 claims description 4
• 229940088594 vitamin Drugs 0.000 claims description 4
• 229930003231 vitamin Natural products 0.000 claims description 4
• 235000013343 vitamin Nutrition 0.000 claims description 4
• 239000011782 vitamin Substances 0.000 claims description 4
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
• 102100032912 CD44 antigen Human genes 0.000 claims description 3
• 206010009944 Colon cancer Diseases 0.000 claims description 3
• 108060006698 EGF receptor Proteins 0.000 claims description 3
• 102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
• 108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
• 238000012650 click reaction Methods 0.000 claims description 3
• 102000006815 folate receptor Human genes 0.000 claims description 3
• 108020005243 folate receptor Proteins 0.000 claims description 3
• 206010017758 gastric cancer Diseases 0.000 claims description 3
• 125000005549 heteroarylene group Chemical group 0.000 claims description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
• 201000011549 stomach cancer Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• 102100029376 Cryptochrome-1 Human genes 0.000 claims description 2
• 102100026280 Cryptochrome-2 Human genes 0.000 claims description 2
• 101000919351 Homo sapiens Cryptochrome-1 Proteins 0.000 claims description 2
• 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 claims description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
• 108090001061 Insulin Proteins 0.000 claims description 2
• 102000004877 Insulin Human genes 0.000 claims description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
• 239000003102 growth factor Substances 0.000 claims description 2
• 229940088597 hormone Drugs 0.000 claims description 2
• 239000005556 hormone Substances 0.000 claims description 2
• 229940125396 insulin Drugs 0.000 claims description 2
• 244000005700 microbiome Species 0.000 claims description 2
• 125000001624 naphthyl group Chemical group 0.000 claims description 2
• 150000003852 triazoles Chemical class 0.000 claims description 2
• 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims 2
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
• 101150013553 CD40 gene Proteins 0.000 claims 1
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
• 241000189662 Calla Species 0.000 claims 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
• 101150084967 EPCAM gene Proteins 0.000 claims 1
• 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 claims 1
• 108090000028 Neprilysin Proteins 0.000 claims 1
• 102000003729 Neprilysin Human genes 0.000 claims 1
• 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 claims 1
• 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
• 206010057644 Testis cancer Diseases 0.000 claims 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
• 150000001735 carboxylic acids Chemical class 0.000 claims 1
• 239000002131 composite material Substances 0.000 claims 1
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• 210000002752 melanocyte Anatomy 0.000 claims 1
• 125000006502 nitrobenzyl group Chemical group 0.000 claims 1
• 235000015097 nutrients Nutrition 0.000 claims 1
• 201000003120 testicular cancer Diseases 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 171
• 238000002360 preparation method Methods 0.000 description 149
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
• 230000002829 reductive effect Effects 0.000 description 79
• 239000000243 solution Substances 0.000 description 79
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 75
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 74
• 239000012299 nitrogen atmosphere Substances 0.000 description 72
• 238000002451 electron ionisation mass spectrometry Methods 0.000 description 70
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 69
• 239000000562 conjugate Substances 0.000 description 63
• 238000005481 NMR spectroscopy Methods 0.000 description 61
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 59
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
• 108090000623 proteins and genes Proteins 0.000 description 54
• 239000007832 Na2SO4 Substances 0.000 description 47
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 47
• 239000012044 organic layer Substances 0.000 description 47
• 229910052938 sodium sulfate Inorganic materials 0.000 description 47
• 235000011152 sodium sulphate Nutrition 0.000 description 47
• 238000004440 column chromatography Methods 0.000 description 44
• 239000007787 solid Substances 0.000 description 43
• 239000000611 antibody drug conjugate Substances 0.000 description 41
• 229940049595 antibody-drug conjugate Drugs 0.000 description 41
• 241000282414 Homo sapiens Species 0.000 description 40
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 39
• 108060003951 Immunoglobulin Proteins 0.000 description 33
• 102000018358 immunoglobulin Human genes 0.000 description 33
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
• 239000003814 drug Substances 0.000 description 31
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
• 201000010099 disease Diseases 0.000 description 28
• 102000004169 proteins and genes Human genes 0.000 description 27
• 230000001225 therapeutic effect Effects 0.000 description 27
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
• 229940079593 drug Drugs 0.000 description 26
• 235000018102 proteins Nutrition 0.000 description 26
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
• 239000011541 reaction mixture Substances 0.000 description 23
• 239000012634 fragment Substances 0.000 description 22
• 238000009472 formulation Methods 0.000 description 21
• 239000003921 oil Substances 0.000 description 21
• 235000019198 oils Nutrition 0.000 description 21
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
• 239000002904 solvent Substances 0.000 description 19
• 238000003756 stirring Methods 0.000 description 19
• 238000011282 treatment Methods 0.000 description 19
• 239000012456 homogeneous solution Substances 0.000 description 18
• 230000008901 benefit Effects 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 16
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
• 230000014509 gene expression Effects 0.000 description 16
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
• 239000012153 distilled water Substances 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 230000001472 cytotoxic effect Effects 0.000 description 14
• 150000007523 nucleic acids Chemical class 0.000 description 14
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
• 239000002775 capsule Substances 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 239000003550 marker Substances 0.000 description 13
• 108020004707 nucleic acids Proteins 0.000 description 13
• 102000039446 nucleic acids Human genes 0.000 description 13
• 239000004480 active ingredient Substances 0.000 description 12
• 150000002148 esters Chemical class 0.000 description 12
• 239000013604 expression vector Substances 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 125000006239 protecting group Chemical group 0.000 description 12
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
• 235000001014 amino acid Nutrition 0.000 description 11
• 239000003242 anti bacterial agent Substances 0.000 description 11
• 239000012267 brine Substances 0.000 description 11
• 239000000872 buffer Substances 0.000 description 11
• 150000001720 carbohydrates Chemical class 0.000 description 11
• 239000000463 material Substances 0.000 description 11
• 239000000546 pharmaceutical excipient Substances 0.000 description 11
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 229940024606 amino acid Drugs 0.000 description 10
• 150000001413 amino acids Chemical class 0.000 description 10
• 229940088710 antibiotic agent Drugs 0.000 description 10
• 239000012298 atmosphere Substances 0.000 description 10
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 10
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 10
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 10
• 239000000651 prodrug Substances 0.000 description 10
• 229940002612 prodrug Drugs 0.000 description 10
• 239000013598 vector Substances 0.000 description 10
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
• 238000010521 absorption reaction Methods 0.000 description 9
• 239000006260 foam Substances 0.000 description 9
• 229940072221 immunoglobulins Drugs 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
• 239000000843 powder Substances 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
• 102000000844 Cell Surface Receptors Human genes 0.000 description 8
• 108010001857 Cell Surface Receptors Proteins 0.000 description 8
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 8
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 8
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 239000012230 colorless oil Substances 0.000 description 8
• 235000019253 formic acid Nutrition 0.000 description 8
• 239000000178 monomer Substances 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 238000003259 recombinant expression Methods 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 239000007921 spray Substances 0.000 description 8
• 229940032147 starch Drugs 0.000 description 8
• 102000003886 Glycoproteins Human genes 0.000 description 7
• 108090000288 Glycoproteins Proteins 0.000 description 7
• 150000001299 aldehydes Chemical class 0.000 description 7
• 235000014633 carbohydrates Nutrition 0.000 description 7
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 239000006185 dispersion Substances 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 238000003379 elimination reaction Methods 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
• DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
• 102100031511 Fc receptor-like protein 2 Human genes 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 6
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 6
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
• 108010076504 Protein Sorting Signals Proteins 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 102100026160 Tomoregulin-2 Human genes 0.000 description 6
• 125000002252 acyl group Chemical group 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 150000001408 amides Chemical class 0.000 description 6
• 239000003963 antioxidant agent Substances 0.000 description 6
• 235000006708 antioxidants Nutrition 0.000 description 6
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 239000006071 cream Substances 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 239000007903 gelatin capsule Substances 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 235000011187 glycerol Nutrition 0.000 description 6
• 108010044426 integrins Proteins 0.000 description 6
• 102000006495 integrins Human genes 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
• 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 5
• 102100032312 Brevican core protein Human genes 0.000 description 5
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 125000000304 alkynyl group Chemical group 0.000 description 5
• 239000002585 base Substances 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 231100000433 cytotoxic Toxicity 0.000 description 5
• 239000002254 cytotoxic agent Substances 0.000 description 5
• 231100000599 cytotoxic agent Toxicity 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 239000008187 granular material Substances 0.000 description 5
• 125000001183 hydrocarbyl group Chemical group 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
• 239000006072 paste Substances 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
• 241000416162 Astragalus gummifer Species 0.000 description 4
• 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 4
• 108010085074 Brevican Proteins 0.000 description 4
• 108700012439 CA9 Proteins 0.000 description 4
• 229940045513 CTLA4 antagonist Drugs 0.000 description 4
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
• 102100020743 Dipeptidase 1 Human genes 0.000 description 4
• 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 4
• 108010087819 Fc receptors Proteins 0.000 description 4
• 102000009109 Fc receptors Human genes 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 4
• 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 4
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 4
• 108091006232 SLC7A5 Proteins 0.000 description 4
• 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• 102000007000 Tenascin Human genes 0.000 description 4
• 108010008125 Tenascin Proteins 0.000 description 4
• 108010022394 Threonine synthase Proteins 0.000 description 4
• 229920001615 Tragacanth Polymers 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 125000004423 acyloxy group Chemical group 0.000 description 4
• 239000000853 adhesive Substances 0.000 description 4
• 230000001070 adhesive effect Effects 0.000 description 4
• 125000004414 alkyl thio group Chemical group 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
• 125000000392 cycloalkenyl group Chemical group 0.000 description 4
• 102000004419 dihydrofolate reductase Human genes 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 150000007857 hydrazones Chemical class 0.000 description 4
• 150000002466 imines Chemical class 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 239000004006 olive oil Substances 0.000 description 4
• 235000008390 olive oil Nutrition 0.000 description 4
• 150000002894 organic compounds Chemical class 0.000 description 4
• KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
• 150000003568 thioethers Chemical class 0.000 description 4
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 235000010487 tragacanth Nutrition 0.000 description 4
• 239000000196 tragacanth Substances 0.000 description 4
• 229940116362 tragacanth Drugs 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• 239000001993 wax Substances 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• 229910052727 yttrium Inorganic materials 0.000 description 4
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
• HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 3
• FPVCVHVTMPCZTH-UHFFFAOYSA-N 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanamine Chemical compound NCCOCCOCCOCCN=[N+]=[N-] FPVCVHVTMPCZTH-UHFFFAOYSA-N 0.000 description 3
• VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 229920001817 Agar Polymers 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 3
• 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 3
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
• 102100024220 CD180 antigen Human genes 0.000 description 3
• 108010065524 CD52 Antigen Proteins 0.000 description 3
• 102100025221 CD70 antigen Human genes 0.000 description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
• 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 3
• 102100032768 Complement receptor type 2 Human genes 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102100033553 Delta-like protein 4 Human genes 0.000 description 3
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 description 3
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 3
• 101000980829 Homo sapiens CD180 antigen Proteins 0.000 description 3
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 3
• 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 3
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 3
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
• 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 3
• 101001064462 Homo sapiens Ephrin type-B receptor 2 Proteins 0.000 description 3
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 3
• 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 3
• 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 3
• 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 3
• 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 3
• 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 3
• 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 description 3
• 102000004157 Hydrolases Human genes 0.000 description 3
• 108090000604 Hydrolases Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 3
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 102100022337 Integrin alpha-V Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 3
• 102000003735 Mesothelin Human genes 0.000 description 3
• 108090000015 Mesothelin Proteins 0.000 description 3
• 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 3
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
• 102100037603 P2X purinoceptor 5 Human genes 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102100029198 SLAM family member 7 Human genes 0.000 description 3
• 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
• 102100035721 Syndecan-1 Human genes 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 3
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
• 230000001594 aberrant effect Effects 0.000 description 3
• 235000010419 agar Nutrition 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 150000004781 alginic acids Chemical class 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 3
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 125000003710 aryl alkyl group Chemical group 0.000 description 3
• 235000010323 ascorbic acid Nutrition 0.000 description 3
• 229960005070 ascorbic acid Drugs 0.000 description 3
• 239000011668 ascorbic acid Substances 0.000 description 3
• 235000012216 bentonite Nutrition 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 229950009964 drozitumab Drugs 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 230000008030 elimination Effects 0.000 description 3
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 208000024908 graft versus host disease Diseases 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 3
• 102000051957 human ERBB2 Human genes 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
• 238000012746 preparative thin layer chromatography Methods 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 238000009097 single-agent therapy Methods 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
• OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
• 150000007970 thio esters Chemical class 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
• 238000001665 trituration Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 2
• GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• HBFPDXXXWANYHN-UHFFFAOYSA-N 1h-1,2-benzodiazepine;1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1.N1N=CC=CC2=CC=CC=C12 HBFPDXXXWANYHN-UHFFFAOYSA-N 0.000 description 2
• YFEXZJKJPFNYKB-UHFFFAOYSA-N 2-(oxolan-2-yloxy)oxolane Chemical compound C1CCOC1OC1OCCC1 YFEXZJKJPFNYKB-UHFFFAOYSA-N 0.000 description 2
• GBWMWHHLQDBPFP-UHFFFAOYSA-N 2-(thian-2-yloxy)thiane Chemical compound S1CCCCC1OC1SCCCC1 GBWMWHHLQDBPFP-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• DTCYSRAEJHGSNY-UHFFFAOYSA-N 2-methoxy-2-(2-methoxypropan-2-yloxy)propane Chemical compound COC(C)(C)OC(C)(C)OC DTCYSRAEJHGSNY-UHFFFAOYSA-N 0.000 description 2
• LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
• RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
• ZQVMXWDQXLWKLE-UHFFFAOYSA-N 4-methoxy-2-(4-methoxyoxan-2-yl)oxyoxane Chemical compound C1C(OC)CCOC1OC1OCCC(OC)C1 ZQVMXWDQXLWKLE-UHFFFAOYSA-N 0.000 description 2
• ZXTCTDQZUWWAEY-UHFFFAOYSA-N 4-methoxy-2-(4-methoxythian-2-yl)oxythiane Chemical compound C1C(OC)CCSC1OC1SCCC(OC)C1 ZXTCTDQZUWWAEY-UHFFFAOYSA-N 0.000 description 2
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
• 102100022749 Aminopeptidase N Human genes 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 101710129514 B-cell differentiation antigen CD72 Proteins 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
• KXSMWPZRKJIOMQ-UHFFFAOYSA-N C=1C=CNC=1.N1N=CC=CC2=CC=CC=C12 Chemical compound C=1C=CNC=1.N1N=CC=CC2=CC=CC=C12 KXSMWPZRKJIOMQ-UHFFFAOYSA-N 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 2
• 101710148283 Choline transporter-like protein 4 Proteins 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
• 102100038083 Endosialin Human genes 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102100031517 Fc receptor-like protein 1 Human genes 0.000 description 2
• 101710120224 Fc receptor-like protein 1 Proteins 0.000 description 2
• 102100022662 Guanylyl cyclase C Human genes 0.000 description 2
• 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 2
• 102000006354 HLA-DR Antigens Human genes 0.000 description 2
• 108010058597 HLA-DR Antigens Proteins 0.000 description 2
• 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 2
• 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 2
• 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
• 101000932213 Homo sapiens Dipeptidase 1 Proteins 0.000 description 2
• 101000884275 Homo sapiens Endosialin Proteins 0.000 description 2
• 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 description 2
• 101100119857 Homo sapiens FCRL2 gene Proteins 0.000 description 2
• 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 2
• 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 2
• 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 description 2
• 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 2
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
• 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 2
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
• 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 2
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
• 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 2
• 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 2
• 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
• 102100033011 Integrin beta-6 Human genes 0.000 description 2
• 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• 108010001831 LDL receptors Proteins 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
• 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
• 102100025096 Mesothelin Human genes 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 102100023123 Mucin-16 Human genes 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 2
• 229910020667 PBr3 Inorganic materials 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
• 102100040122 Proline-rich protein 4 Human genes 0.000 description 2
• 101710124304 Proline-rich protein 4 Proteins 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 102000014128 RANK Ligand Human genes 0.000 description 2
• 108010025832 RANK Ligand Proteins 0.000 description 2
• 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
• 108091006576 SLC34A2 Proteins 0.000 description 2
• 229910006124 SOCl2 Inorganic materials 0.000 description 2
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 108010017622 Somatomedin Receptors Proteins 0.000 description 2
• 102000004584 Somatomedin Receptors Human genes 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
• 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 2
• 108010055044 Tetanus Toxin Proteins 0.000 description 2
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 101710120037 Toxin CcdB Proteins 0.000 description 2
• 108010033576 Transferrin Receptors Proteins 0.000 description 2
• 102100031228 Transient receptor potential cation channel subfamily M member 4 Human genes 0.000 description 2
• 102100033579 Trophoblast glycoprotein Human genes 0.000 description 2
• 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
• 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
• 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 2
• LPTITAGPBXDDGR-LYYZXLFJSA-N [(2r,3s,4s,5r,6s)-3,4,5,6-tetraacetyloxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O LPTITAGPBXDDGR-LYYZXLFJSA-N 0.000 description 2
• WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 108010003196 alanyl-prolyl-arginyl-prolyl-glycine Proteins 0.000 description 2
• 125000006241 alcohol protecting group Chemical group 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 238000005842 biochemical reaction Methods 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 2
• JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 2
• JZUVESQYEHERMD-UHFFFAOYSA-N bis[(4-nitrophenyl)methyl] carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JZUVESQYEHERMD-UHFFFAOYSA-N 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 230000002301 combined effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 150000001945 cysteines Chemical class 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 229960001484 edetic acid Drugs 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
• 229940093471 ethyl oleate Drugs 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 150000002270 gangliosides Chemical class 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 150000002334 glycols Chemical class 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• VEIWYFRREFUNRC-UHFFFAOYSA-N hydron;piperidine;chloride Chemical compound [Cl-].C1CC[NH2+]CC1 VEIWYFRREFUNRC-UHFFFAOYSA-N 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 2
• NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
• CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 2
• CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 239000002324 mouth wash Substances 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 239000012457 nonaqueous media Substances 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 150000002895 organic esters Chemical class 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
• IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 229950010773 pidilizumab Drugs 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 150000004804 polysaccharides Chemical class 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 2
• 239000012713 reactive precursor Substances 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 2
• XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical class CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
• 229940118376 tetanus toxin Drugs 0.000 description 2
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 150000003573 thiols Chemical group 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 description 2
• 229940066528 trichloroacetate Drugs 0.000 description 2
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 231100000588 tumorigenic Toxicity 0.000 description 2
• 230000000381 tumorigenic effect Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
• JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• HIPYHINICCKLGX-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=CC(OC)=C1 HIPYHINICCKLGX-UHFFFAOYSA-N 0.000 description 1
• YVOBGLMMNWZYCL-UHFFFAOYSA-N (3-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=CC([N+]([O-])=O)=C1 YVOBGLMMNWZYCL-UHFFFAOYSA-N 0.000 description 1
• BWKMGYQJPOAASG-VIFPVBQESA-N (3s)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-VIFPVBQESA-N 0.000 description 1
• SDEOSHAQCMPJIJ-UHFFFAOYSA-N (4-methoxyphenyl)methyl carbamate Chemical compound COC1=CC=C(COC(N)=O)C=C1 SDEOSHAQCMPJIJ-UHFFFAOYSA-N 0.000 description 1
• NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
• DIPVWSTVQDONTF-NUAZBEIESA-N (8E)-2-[(2S,3R,4R,5R,6S)-3,4-dihydroxy-6-methyl-5-(methylamino)oxan-2-yl]oxy-6-methoxy-8-propylidene-6,6a,7,9-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound CC\C=C1/CC2C(Nc3ccc(O[C@@H]4O[C@@H](C)[C@H](NC)[C@@H](O)[C@H]4O)cc3C(=O)N2C1)OC DIPVWSTVQDONTF-NUAZBEIESA-N 0.000 description 1
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
• UQVNRKBFAXNOGA-OHLDGCSVSA-N (Z)-tomaymycin Chemical compound CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C/C)C[C@@H]12 UQVNRKBFAXNOGA-OHLDGCSVSA-N 0.000 description 1
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• ITFCEERPJPLHPQ-UHFFFAOYSA-N 1,3-dichloro-2-[(2,6-dichlorophenyl)methoxymethyl]benzene Chemical compound ClC1=CC=CC(Cl)=C1COCC1=C(Cl)C=CC=C1Cl ITFCEERPJPLHPQ-UHFFFAOYSA-N 0.000 description 1
• ZKMQTXLYCBRSMV-UHFFFAOYSA-N 1-(4-bromophenyl)-2-[2-(4-bromophenyl)-2-oxoethoxy]ethanone Chemical compound C1=CC(Br)=CC=C1C(=O)COCC(=O)C1=CC=C(Br)C=C1 ZKMQTXLYCBRSMV-UHFFFAOYSA-N 0.000 description 1
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
• WCZCUFUSTALRPJ-UHFFFAOYSA-N 1-[[naphthalen-1-yl(diphenyl)methoxy]-diphenylmethyl]naphthalene Chemical compound C=1C=CC=CC=1C(C=1C2=CC=CC=C2C=CC=1)(C=1C=CC=CC=1)OC(C=1C2=CC=CC=C2C=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WCZCUFUSTALRPJ-UHFFFAOYSA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• BQLHMMQUVJCTAN-UHFFFAOYSA-N 1-chloro-3-methoxypropane Chemical compound COCCCCl BQLHMMQUVJCTAN-UHFFFAOYSA-N 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
• SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
• IGHQOFUUDYGVMD-UHFFFAOYSA-N 1-methoxy-4-[[(4-methoxyphenyl)-diphenylmethoxy]-diphenylmethyl]benzene Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC(OC)=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 IGHQOFUUDYGVMD-UHFFFAOYSA-N 0.000 description 1
• ARARQWKFKMWCDL-UHFFFAOYSA-N 1-nitro-2-[(2-nitrophenyl)methoxymethyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1COCC1=CC=CC=C1[N+]([O-])=O ARARQWKFKMWCDL-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
• QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• LLSWESFIHBBZME-UHFFFAOYSA-N 2,2-dichloro-1-(2,2-dichloro-1,1-difluoroethoxy)-1,1-difluoroethane Chemical compound ClC(Cl)C(F)(F)OC(F)(F)C(Cl)Cl LLSWESFIHBBZME-UHFFFAOYSA-N 0.000 description 1
• KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 1
• JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 1
• KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
• FCPBCJMDBJLGQA-AJNGGQMLSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@H](C(=O)NCC(O)=O)CCC1 FCPBCJMDBJLGQA-AJNGGQMLSA-N 0.000 description 1
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
• WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
• KNPXJNJURBXQLV-UHFFFAOYSA-N 2-carbamoylbutanoic acid Chemical compound CCC(C(N)=O)C(O)=O KNPXJNJURBXQLV-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
• HNFSPSWQNZVCTB-UHFFFAOYSA-N 2-methyl-2-propan-2-yloxypropane Chemical compound CC(C)OC(C)(C)C HNFSPSWQNZVCTB-UHFFFAOYSA-N 0.000 description 1
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
• QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
• GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
• CHZPJUSFUDUEMZ-UHFFFAOYSA-N 3-acetylbenzoic acid Chemical compound CC(=O)C1=CC=CC(C(O)=O)=C1 CHZPJUSFUDUEMZ-UHFFFAOYSA-N 0.000 description 1
• NXZBZWZORYEIJL-UHFFFAOYSA-N 3-formyl-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(C=O)=C1 NXZBZWZORYEIJL-UHFFFAOYSA-N 0.000 description 1
• 102100040842 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Human genes 0.000 description 1
• QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
• JTSSUEWTRDWHGY-UHFFFAOYSA-N 4-(pyridin-4-ylmethoxymethyl)pyridine Chemical compound C=1C=NC=CC=1COCC1=CC=NC=C1 JTSSUEWTRDWHGY-UHFFFAOYSA-N 0.000 description 1
• QBHDSQZASIBAAI-UHFFFAOYSA-N 4-acetylbenzoic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)C=C1 QBHDSQZASIBAAI-UHFFFAOYSA-N 0.000 description 1
• XGAFCCUNHIMIRV-UHFFFAOYSA-N 4-chloropyridine;hydron;chloride Chemical compound Cl.ClC1=CC=NC=C1 XGAFCCUNHIMIRV-UHFFFAOYSA-N 0.000 description 1
• NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 1
• WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 1
• JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical class CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
• 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
• DVRKZTKTNYRYLF-UHFFFAOYSA-N 9-methoxyanthracene Chemical compound C1=CC=C2C(OC)=C(C=CC=C3)C3=CC2=C1 DVRKZTKTNYRYLF-UHFFFAOYSA-N 0.000 description 1
• ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
• 108010005465 AC133 Antigen Proteins 0.000 description 1
• 102000005908 AC133 Antigen Human genes 0.000 description 1
• PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 241001436679 Adama Species 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 102000001921 Aminopeptidase P Human genes 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 102100034608 Angiopoietin-2 Human genes 0.000 description 1
• 108010048036 Angiopoietin-2 Proteins 0.000 description 1
• 102000009840 Angiopoietins Human genes 0.000 description 1
• 108010009906 Angiopoietins Proteins 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 1
• 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 1
• 101100082449 Arabidopsis thaliana PBL21 gene Proteins 0.000 description 1
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
• 101100208111 Arabidopsis thaliana TRX5 gene Proteins 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
• DDPXDCKYWDGZAL-BQBZGAKWSA-N Asn-Gly-Arg Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N DDPXDCKYWDGZAL-BQBZGAKWSA-N 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
• 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
• 101710187595 B-cell receptor CD22 Proteins 0.000 description 1
• 108010074708 B7-H1 Antigen Proteins 0.000 description 1
• 229910015844 BCl3 Inorganic materials 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010073466 Bombesin Receptors Proteins 0.000 description 1
• 102000010183 Bradykinin receptor Human genes 0.000 description 1
• 108050001736 Bradykinin receptor Proteins 0.000 description 1
• 101710140080 Brevican core protein Proteins 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 102100032556 C-type lectin domain family 14 member A Human genes 0.000 description 1
• 102100026197 C-type lectin domain family 2 member D Human genes 0.000 description 1
• 108091005932 CCKBR Proteins 0.000 description 1
• 108010049990 CD13 Antigens Proteins 0.000 description 1
• 102100027207 CD27 antigen Human genes 0.000 description 1
• 102100038078 CD276 antigen Human genes 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 101100222017 Candida albicans (strain SC5314 / ATCC MYA-2876) CSA2 gene Proteins 0.000 description 1
• 101100083071 Candida albicans (strain SC5314 / ATCC MYA-2876) PGA7 gene Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 238000007303 Carboni reaction Methods 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102100035904 Caspase-1 Human genes 0.000 description 1
• 108090000426 Caspase-1 Proteins 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 102000003908 Cathepsin D Human genes 0.000 description 1
• 108090000258 Cathepsin D Proteins 0.000 description 1
• 102000004171 Cathepsin K Human genes 0.000 description 1
• 108090000625 Cathepsin K Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 229940123150 Chelating agent Drugs 0.000 description 1
• 229930184471 Chicamycin Natural products 0.000 description 1
• GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 108010089335 Cholecystokinin A Receptor Proteins 0.000 description 1
• 102100034927 Cholecystokinin receptor type A Human genes 0.000 description 1
• 102100030886 Complement receptor type 1 Human genes 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 230000007118 DNA alkylation Effects 0.000 description 1
• 102100036466 Delta-like protein 3 Human genes 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
• 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical class SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• 108010043648 Discoidin Domain Receptors Proteins 0.000 description 1
• 102000002706 Discoidin Domain Receptors Human genes 0.000 description 1
• 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 229940126626 Ektomab Drugs 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 102000010180 Endothelin receptor Human genes 0.000 description 1
• 108050001739 Endothelin receptor Proteins 0.000 description 1
• 108010055196 EphA2 Receptor Proteins 0.000 description 1
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 1
• 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 229940126611 FBTA05 Drugs 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
• 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000010451 Folate receptor alpha Human genes 0.000 description 1
• 108050001931 Folate receptor alpha Proteins 0.000 description 1
• 102000005698 Frizzled receptors Human genes 0.000 description 1
• 108010045438 Frizzled receptors Proteins 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102100039717 G antigen 1 Human genes 0.000 description 1
• 102100025361 G-protein coupled receptor 161 Human genes 0.000 description 1
• 102100033859 G-protein coupled receptor 78 Human genes 0.000 description 1
• 102000004300 GABA-A Receptors Human genes 0.000 description 1
• 108090000839 GABA-A Receptors Proteins 0.000 description 1
• 108700012941 GNRH1 Proteins 0.000 description 1
• 108010001517 Galectin 3 Proteins 0.000 description 1
• 102100039558 Galectin-3 Human genes 0.000 description 1
• 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 description 1
• 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 101710088083 Glomulin Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 229920002306 Glycocalyx Polymers 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
• 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 101000893701 Homo sapiens 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Proteins 0.000 description 1
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
• 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
• 101000942280 Homo sapiens C-type lectin domain family 14 member A Proteins 0.000 description 1
• 101000912615 Homo sapiens C-type lectin domain family 2 member D Proteins 0.000 description 1
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
• 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
• 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
• 101000857756 Homo sapiens G-protein coupled receptor 161 Proteins 0.000 description 1
• 101001069603 Homo sapiens G-protein coupled receptor 78 Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101001044893 Homo sapiens Interleukin-20 receptor subunit alpha Proteins 0.000 description 1
• 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
• 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
• 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
• 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
• 101100420560 Homo sapiens SLC39A6 gene Proteins 0.000 description 1
• 101000835984 Homo sapiens SLIT and NTRK-like protein 6 Proteins 0.000 description 1
• 101000604039 Homo sapiens Sodium-dependent phosphate transport protein 2B Proteins 0.000 description 1
• 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 description 1
• 101000829138 Homo sapiens Somatostatin receptor type 3 Proteins 0.000 description 1
• 101000829153 Homo sapiens Somatostatin receptor type 5 Proteins 0.000 description 1
• 101000837401 Homo sapiens T-cell leukemia/lymphoma protein 1A Proteins 0.000 description 1
• 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 108010041012 Integrin alpha4 Proteins 0.000 description 1
• 108010041014 Integrin alpha5 Proteins 0.000 description 1
• 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
• 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 description 1
• 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 description 1
• 102000004195 Isomerases Human genes 0.000 description 1
• 108090000769 Isomerases Proteins 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• 229930064664 L-arginine Natural products 0.000 description 1
• 235000014852 L-arginine Nutrition 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
• 108010021290 LHRH Receptors Proteins 0.000 description 1
• 102000008238 LHRH Receptors Human genes 0.000 description 1
• 101150086425 LYPD3 gene Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 102000004317 Lyases Human genes 0.000 description 1
• 108090000856 Lyases Proteins 0.000 description 1
• 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 102000051089 Melanotransferrin Human genes 0.000 description 1
• 108700038051 Melanotransferrin Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 108010047562 NGR peptide Proteins 0.000 description 1
• 229910017852 NH2NH2 Inorganic materials 0.000 description 1
• 102100035486 Nectin-4 Human genes 0.000 description 1
• 101710043865 Nectin-4 Proteins 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 108091005461 Nucleic proteins Chemical group 0.000 description 1
• 102100021010 Nucleolin Human genes 0.000 description 1
• CUOGJZKKYJWSNH-UHFFFAOYSA-N O=S(=CC1=CC=CC=C1)=O.Cl Chemical compound O=S(=CC1=CC=CC=C1)=O.Cl CUOGJZKKYJWSNH-UHFFFAOYSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 229910002666 PdCl2 Inorganic materials 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 101710180074 Pepsin F Proteins 0.000 description 1
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 108010092528 Phosphate Transport Proteins Proteins 0.000 description 1
• 102000016462 Phosphate Transport Proteins Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 108010080192 Purinergic Receptors Proteins 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 108091006938 SLC39A6 Proteins 0.000 description 1
• 102100025504 SLIT and NTRK-like protein 6 Human genes 0.000 description 1
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 102000003800 Selectins Human genes 0.000 description 1
• 108090000184 Selectins Proteins 0.000 description 1
• 102100032780 Semaphorin-5B Human genes 0.000 description 1
• 101710199399 Semaphorin-5B Proteins 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
• 102100028662 Sigma intracellular receptor 2 Human genes 0.000 description 1
• 101710109012 Sigma intracellular receptor 2 Proteins 0.000 description 1
• 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
• 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 108050001286 Somatostatin Receptor Proteins 0.000 description 1
• 102000011096 Somatostatin receptor Human genes 0.000 description 1
• 102100029329 Somatostatin receptor type 1 Human genes 0.000 description 1
• 102100023802 Somatostatin receptor type 2 Human genes 0.000 description 1
• 102100023803 Somatostatin receptor type 3 Human genes 0.000 description 1
• 102100023801 Somatostatin receptor type 4 Human genes 0.000 description 1
• 102100023806 Somatostatin receptor type 5 Human genes 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 description 1
• 208000000277 Splenic Neoplasms Diseases 0.000 description 1
• 101100523267 Staphylococcus aureus qacC gene Proteins 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 235000019486 Sunflower oil Nutrition 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• 102100028676 T-cell leukemia/lymphoma protein 1A Human genes 0.000 description 1
• 102000003618 TRPM4 Human genes 0.000 description 1
• 108010014401 TWEAK Receptor Proteins 0.000 description 1
• 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 101710098080 Teratocarcinoma-derived growth factor Proteins 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102100030859 Tissue factor Human genes 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
• 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
• 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 1
• 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 description 1
• 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 description 1
• 102000025309 Type 2 Angiotensin Receptor Human genes 0.000 description 1
• 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 1
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 244000077923 Vaccinium vitis idaea Species 0.000 description 1
• 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
• 238000005411 Van der Waals force Methods 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
• 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
• 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
• 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
• 102100035071 Vimentin Human genes 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003270 Vitamin B Natural products 0.000 description 1
• 229930003779 Vitamin B12 Natural products 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 108010038900 X-Pro aminopeptidase Proteins 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
• 229950005186 abagovomab Drugs 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• PPZYBFUYKJPWBY-UHFFFAOYSA-N acetylene azide Chemical group C#C.[N-]=[N+]=[N-] PPZYBFUYKJPWBY-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 229950009084 adecatumumab Drugs 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 150000001335 aliphatic alkanes Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• 229950009106 altumomab Drugs 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 229950001537 amatuximab Drugs 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 201000007538 anal carcinoma Diseases 0.000 description 1
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000003972 antineoplastic antibiotic Substances 0.000 description 1
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
• 229950003145 apolizumab Drugs 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 210000001742 aqueous humor Anatomy 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
• 229910001863 barium hydroxide Inorganic materials 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 229950007843 bavituximab Drugs 0.000 description 1
• 229960003270 belimumab Drugs 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• DUXANUSOCMOJSI-UHFFFAOYSA-N benzhydryl carbamate Chemical compound C=1C=CC=CC=1C(OC(=O)N)C1=CC=CC=C1 DUXANUSOCMOJSI-UHFFFAOYSA-N 0.000 description 1
• 150000001557 benzodiazepines Chemical class 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• KVPFKMBYCSISTN-UHFFFAOYSA-N benzylsulfanylformic acid Chemical compound OC(=O)SCC1=CC=CC=C1 KVPFKMBYCSISTN-UHFFFAOYSA-N 0.000 description 1
• 229950010559 besilesomab Drugs 0.000 description 1
• CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 description 1
• 229950002903 bivatuzumab Drugs 0.000 description 1
• 229930189065 blasticidin Natural products 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
• UGDWJDYCTNYZEU-UHFFFAOYSA-N butanedioic acid;ethane-1,2-diol Chemical compound OCCO.OC(=O)CCC(O)=O.OC(=O)CCC(O)=O UGDWJDYCTNYZEU-UHFFFAOYSA-N 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229940095643 calcium hydroxide Drugs 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000004452 carbocyclyl group Chemical group 0.000 description 1
• YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229950000771 carlumab Drugs 0.000 description 1
• 229960004203 carnitine Drugs 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 229960000419 catumaxomab Drugs 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 238000010382 chemical cross-linking Methods 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
• MNKYQPOFRKPUAE-UHFFFAOYSA-N chloro(triphenyl)silane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 MNKYQPOFRKPUAE-UHFFFAOYSA-N 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 229950010905 citatuzumab bogatox Drugs 0.000 description 1
• 229950006647 cixutumumab Drugs 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 229950007276 conatumumab Drugs 0.000 description 1
• 230000030944 contact inhibition Effects 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• OCDXZFSOHJRGIL-UHFFFAOYSA-N cyclohexyloxycyclohexane Chemical compound C1CCCCC1OC1CCCCC1 OCDXZFSOHJRGIL-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229950007409 dacetuzumab Drugs 0.000 description 1
• 229960002482 dalotuzumab Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960002887 deanol Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 229920006237 degradable polymer Polymers 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 229940127276 delta-like ligand 3 Drugs 0.000 description 1
• 229950007998 demcizumab Drugs 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 229950008962 detumomab Drugs 0.000 description 1
• AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 125000005131 dialkylammonium group Chemical group 0.000 description 1
• MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
• IZDJJEMZQZQQQQ-UHFFFAOYSA-N dicopper;tetranitrate;pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O IZDJJEMZQZQQQQ-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 235000019621 digestibility Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• DOSDTCPDBPRFHQ-UHFFFAOYSA-N dimethyl 5-hydroxybenzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(O)=CC(C(=O)OC)=C1 DOSDTCPDBPRFHQ-UHFFFAOYSA-N 0.000 description 1
• OARYFQYHTWCNQO-UHFFFAOYSA-N dimethyl(propan-2-yloxy)silane Chemical compound CC(C)O[SiH](C)C OARYFQYHTWCNQO-UHFFFAOYSA-N 0.000 description 1
• MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical compound OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 description 1
• 150000002009 diols Chemical group 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229950011453 dusigitumab Drugs 0.000 description 1
• 229950000006 ecromeximab Drugs 0.000 description 1
• 229960002224 eculizumab Drugs 0.000 description 1
• 229960001776 edrecolomab Drugs 0.000 description 1
• 230000005288 electromagnetic effect Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 229950003048 enavatuzumab Drugs 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229950001752 enoticumab Drugs 0.000 description 1
• 229950010640 ensituximab Drugs 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 230000008472 epithelial growth Effects 0.000 description 1
• 229950001757 epitumomab Drugs 0.000 description 1
• XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
• 229950009760 epratuzumab Drugs 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 239000003885 eye ointment Substances 0.000 description 1
• 229950009929 farletuzumab Drugs 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 229950002846 ficlatuzumab Drugs 0.000 description 1
• 229950008085 figitumumab Drugs 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 229950010320 flanvotumab Drugs 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 229950004003 fresolimumab Drugs 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229950001109 galiximab Drugs 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 229950004896 ganitumab Drugs 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 229950002026 girentuximab Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 210000004517 glycocalyx Anatomy 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 229950006359 icrucumab Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 229950002200 igovomab Drugs 0.000 description 1
• 229950005646 imgatuzumab Drugs 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 229910017053 inorganic salt Inorganic materials 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 108010093036 interleukin receptors Proteins 0.000 description 1
• 102000002467 interleukin receptors Human genes 0.000 description 1
• 108010027445 interleukin-22 receptor Proteins 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 229950001014 intetumumab Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 229950010939 iratumumab Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 229950000518 labetuzumab Drugs 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 229940058352 levulinate Drugs 0.000 description 1
• 229950002884 lexatumumab Drugs 0.000 description 1
• 229950002950 lintuzumab Drugs 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
• 235000019136 lipoic acid Nutrition 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• SQEHCNOBYLQFTG-UHFFFAOYSA-M lithium;thiophene-2-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CS1 SQEHCNOBYLQFTG-UHFFFAOYSA-M 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 201000002250 liver carcinoma Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 208000019420 lymphoid neoplasm Diseases 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 229950001869 mapatumumab Drugs 0.000 description 1
• 229950003135 margetuximab Drugs 0.000 description 1
• 229950008001 matuzumab Drugs 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• XKKFHYIHXAEDLW-UHFFFAOYSA-N methoxymethylcarbamic acid Chemical compound COCNC(O)=O XKKFHYIHXAEDLW-UHFFFAOYSA-N 0.000 description 1
• WRVLBJXFSHALRZ-FUVGGWJZSA-N methyl (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoate Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 WRVLBJXFSHALRZ-FUVGGWJZSA-N 0.000 description 1
• SANNKFASHWONFD-LURJTMIESA-N methyl (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)[C@H](CO)NC(=O)OC(C)(C)C SANNKFASHWONFD-LURJTMIESA-N 0.000 description 1
• DQHIGEQXJBMKKY-UHFFFAOYSA-N methyl 2,4-dibromobutanoate Chemical compound COC(=O)C(Br)CCBr DQHIGEQXJBMKKY-UHFFFAOYSA-N 0.000 description 1
• AAJZXPWBILCHAW-UHFFFAOYSA-N methyl 5-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(Br)=C1 AAJZXPWBILCHAW-UHFFFAOYSA-N 0.000 description 1
• CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
• VWKNUUOGGLNRNZ-UHFFFAOYSA-N methylbimane Chemical compound CC1=C(C)C(=O)N2N1C(C)=C(C)C2=O VWKNUUOGGLNRNZ-UHFFFAOYSA-N 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 229950003734 milatuzumab Drugs 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229950002142 minretumomab Drugs 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229950003063 mitumomab Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
• 229950005674 modotuximab Drugs 0.000 description 1
• 229950007699 mogamulizumab Drugs 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000002200 mouth mucosa Anatomy 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
• 108010025496 mucin receptor Proteins 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KWBIXTIBYFUAGV-UHFFFAOYSA-M n-ethylcarbamate Chemical compound CCNC([O-])=O KWBIXTIBYFUAGV-UHFFFAOYSA-M 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229950003027 nacolomab tafenatox Drugs 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229960000513 necitumumab Drugs 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 229950002697 nesvacumab Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
• 229950010203 nimotuzumab Drugs 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 108010044762 nucleolin Proteins 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 239000012434 nucleophilic reagent Substances 0.000 description 1
• 239000007764 o/w emulsion Substances 0.000 description 1
• 229960003347 obinutuzumab Drugs 0.000 description 1
• 229950009090 ocaratuzumab Drugs 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229950002104 ontuxizumab Drugs 0.000 description 1
• 229940042125 oral ointment Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 229950007283 oregovomab Drugs 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 150000002905 orthoesters Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 229950000121 otlertuzumab Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• CHNLPLHJUPMEOI-UHFFFAOYSA-N oxolane;trifluoroborane Chemical compound FB(F)F.C1CCOC1 CHNLPLHJUPMEOI-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229960003540 oxyquinoline Drugs 0.000 description 1
• 125000006503 p-nitrobenzyl group Chemical class [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 229940126618 pankomab Drugs 0.000 description 1
• 229940055726 pantothenic acid Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229950004260 parsatuzumab Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 229950010966 patritumab Drugs 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960002621 pembrolizumab Drugs 0.000 description 1
• 229960005570 pemtumomab Drugs 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 208000030940 penile carcinoma Diseases 0.000 description 1
• 201000008174 penis carcinoma Diseases 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 229940067082 pentetate Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 201000002628 peritoneum cancer Diseases 0.000 description 1
• 229960002087 pertuzumab Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• GOSXBCKRSJOJQW-UHFFFAOYSA-N phenylmethoxymethanethioic s-acid Chemical compound SC(=O)OCC1=CC=CC=C1 GOSXBCKRSJOJQW-UHFFFAOYSA-N 0.000 description 1
• TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• CKVRJOBUMGJKDE-UHFFFAOYSA-N phenylsulfanylmethoxymethylsulfanylbenzene Chemical compound C=1C=CC=CC=1SCOCSC1=CC=CC=C1 CKVRJOBUMGJKDE-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 125000001095 phosphatidyl group Chemical group 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920001855 polyketal Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
• 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 229950009904 pritumumab Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000135 prohibitive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 239000003909 protein kinase inhibitor Substances 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 229960003581 pyridoxal Drugs 0.000 description 1
• 235000008164 pyridoxal Nutrition 0.000 description 1
• 239000011674 pyridoxal Substances 0.000 description 1
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• AHNVDMNIJVXKML-UHFFFAOYSA-N quinolin-8-yl benzenesulfonate Chemical compound C=1C=CC2=CC=CN=C2C=1OS(=O)(=O)C1=CC=CC=C1 AHNVDMNIJVXKML-UHFFFAOYSA-N 0.000 description 1
• FLCPORVHXQFBHT-UHFFFAOYSA-N quinolin-8-yl carbamate Chemical compound C1=CN=C2C(OC(=O)N)=CC=CC2=C1 FLCPORVHXQFBHT-UHFFFAOYSA-N 0.000 description 1
• 229950011613 racotumomab Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 229950011639 radretumab Drugs 0.000 description 1
• 229960002633 ramucirumab Drugs 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 235000019192 riboflavin Nutrition 0.000 description 1
• 239000002151 riboflavin Substances 0.000 description 1
• 229960002477 riboflavin Drugs 0.000 description 1
• 229950003238 rilotumumab Drugs 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 229950001808 robatumumab Drugs 0.000 description 1
• PIDYQAYNSQSDQY-UHFFFAOYSA-N s-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 201000003804 salivary gland carcinoma Diseases 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 229940065287 selenium compound Drugs 0.000 description 1
• 150000003343 selenium compounds Chemical class 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 229950008834 seribantumab Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• RAGFPHFDFVNLCG-INYQBOQCSA-N sibiromycin Chemical compound O[C@@H]1[C@@](O)(C)[C@@H](NC)[C@H](C)O[C@H]1OC(C(=C1O)C)=CC(C2=O)=C1N[C@H](O)[C@H]1N2C=C(\C=C\C)C1 RAGFPHFDFVNLCG-INYQBOQCSA-N 0.000 description 1
• RAGFPHFDFVNLCG-UHFFFAOYSA-N sibiromycin Natural products OC1C(O)(C)C(NC)C(C)OC1OC(C(=C1O)C)=CC(C2=O)=C1NC(O)C1N2C=C(C=CC)C1 RAGFPHFDFVNLCG-UHFFFAOYSA-N 0.000 description 1
• 229950008684 sibrotuzumab Drugs 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 229960003323 siltuximab Drugs 0.000 description 1
• QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000017550 sodium carbonate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 108010064556 somatostatin receptor subtype-4 Proteins 0.000 description 1
• 108010082379 somatostatin receptor type 1 Proteins 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
• 201000002471 spleen cancer Diseases 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 210000004085 squamous epithelial cell Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000011255 standard chemotherapy Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000002600 sunflower oil Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 101150047061 tag-72 gene Proteins 0.000 description 1
• 229950001603 taplitumomab paptox Drugs 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229950010259 teprotumumab Drugs 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
• UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229960002663 thioctic acid Drugs 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 229950004742 tigatuzumab Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229950005808 tovetumab Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 125000005208 trialkylammonium group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 150000003628 tricarboxylic acids Chemical class 0.000 description 1
• FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229950004593 ublituximab Drugs 0.000 description 1
• 229950005972 urelumab Drugs 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000012991 uterine carcinoma Diseases 0.000 description 1
• BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
• TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
• 229950008718 vantictumab Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• 239000000052 vinegar Substances 0.000 description 1
• 235000021419 vinegar Nutrition 0.000 description 1
• LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
• 150000008127 vinyl sulfides Chemical class 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 229950001212 volociximab Drugs 0.000 description 1
• 229950006959 vorsetuzumab Drugs 0.000 description 1
• 229950003511 votumumab Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 235000014692 zinc oxide Nutrition 0.000 description 1
• 229950007157 zolbetuximab Drugs 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1